Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,670 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06900647RecruitingPhase 1
Bortezomib plus cisplatin for advanced breast cancer
This study tests a combination of two drugs, bortezomib and cisplatin, for people with breast cancer that has spread or come back after standard treatments. The goal is to see if this combination can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06934057RecruitingPhase 4
Cabozantinib and Nivolumab for older adults with kidney cancer
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
AngersAges 70 years+ - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT06975384Recruiting
Sleep and lung cancer treatment outcome study
This study looks at how sleep disturbances affect how well lung cancer treatments work. It may help doctors understand if improving sleep can lead to better treatment results.
Changsha, HunanAges 18 years+ - NCT06991946Recruiting
Genomic profiling for metastatic breast cancer in Spain
This study looks at how genetic testing of your tumor might affect the treatment plan for your metastatic breast cancer. It aims to help doctors choose the best therapy based on your tumor's profile.
Barcelona, BarcelonaAges 18 years+ - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT07032584Recruiting
Tele-rehab for rural men with metastatic prostate cancer
This trial tests a home-based exercise and support program delivered by phone or video for men with metastatic prostate cancer living in rural areas. The goal is to see if this approach improves quality of life and physical function compared to standard care.
Salt Lake City, UtahAges 21 years+ - NCT07055399RecruitingPhase 2
Neoadjuvant immunotherapy with two drugs plus chemo for cervical cancer
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Fuzhou, FujianAges 18–70 - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07100600RecruitingPhase 2
Targeted drug with or without radiation for HER2-positive breast cancer brain tumors
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
Zhengzhou, HenanAges 18 years+ - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT07193394RecruitingPhase 2
Tucatinib and trastuzumab for HER3-mutant breast cancer
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
BordeauxAges 18 years+ - NCT07283835RecruitingPhase 2
Study of Cretostimogene for non-muscle invasive bladder cancer
This trial tests a new drug, Cretostimogene, for people with a type of bladder cancer that hasn't spread into the muscle layer (non-muscle invasive) and has not responded to standard BCG treatment. The goal is to see if this drug can help control the cancer and avoid the need for bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07371611RecruitingPhase 3
Sintilimab plus chemo before and after surgery for advanced oral cancer
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07607119Recruiting
PULSAR radiation plus immunotherapy for advanced gastric cancer
This trial tests combining PULSAR (a type of radiation therapy) with immunotherapy drugs to treat gastric (stomach) cancer that cannot be surgically removed. You must have already completed at least 3 months of chemotherapy with immunotherapy and shown no cancer growth to qualify.
Seoul, Select Province/StateAges 19 years+ - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
Combination therapy for metastatic colorectal cancer with RAS mutation
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
BeijingAges 18–70 - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT07225309Recruiting
Meaning-Centered Therapy for Mexican Adults with Advanced Cancer
This study tests a therapy program called Meaning-Centered Therapy designed to help adults in Mexico with advanced cancer find meaning and improve their well-being. It involves sessions delivered by trained providers at the National Cancer Institute in Mexico (INCan).
New York, New YorkAges 18 years+ - NCT02906943Recruiting
Testing cancer tissue to guide targeted treatment choices
This trial studies advanced solid tumors by using stored tumor samples to look for molecular clues. The goal is to help doctors better choose cancer treatments that may work for your specific tumor.
Hamilton, OntarioAges 18 years+ - NCT04703101RecruitingPhase 1
Short radiation plus chemo for stage II–III rectal cancer
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT07433660Recruiting
WellSpan Cancer Quality of Life Study
This study looks at quality of life in people recently diagnosed with cancer. It aims to understand how cancer and its treatment affect daily life and well-being.
Chambersburg, PennsylvaniaAges 18 years+ - NCT04169763RecruitingPhase 1
Nelfinavir with chemo and radiation for vulvar cancer
This Phase 1 trial tests whether adding nelfinavir to standard chemo (cisplatin) and external-beam radiation can treat locally advanced vulvar cancer that cannot be removed with surgery. It’s designed to check safety and how well the treatment can work for this situation.
Houston, TexasAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,670 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.